- Eli Lilly Canada has received a positive reimbursement recommendation from CDA-AMC for Kisunla (donanemab), administered every four weeks, for eligible adults with early symptomatic Alzheimer’s disease.
- The recommendation recognizes donanemab as a disease-modifying therapy that addresses an unmet clinical need by slowing cognitive and functional decline in patients with early Alzheimer’s disease.
- The decision marks an important access milestone, making Canada one of the first internationally recognized HTA bodies to issue a positive reimbursement recommendation for donanemab.
- Lilly will work with governments and healthcare stakeholders to advance patient access. The recommendation also brings the treatment closer to eligible Canadians, pending provincial reimbursement decisions.
Takeaways:
The positive reimbursement recommendation strengthens Kisunla’s commercial prospects in Canada and represents a significant step toward broader access to disease-modifying Alzheimer’s treatments. The decision could accelerate adoption of donanemab by supporting its inclusion in public reimbursement programs, although provincial funding decisions remain necessary. It also reinforces Eli Lilly’s position in the emerging Alzheimer’s therapeutics market and could encourage further competition and investment in treatments targeting early-stage disease progression.
Source: CA Newswire
